ArticleFrontiers in pharmacology2025

Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody.

Jia-Xin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.